Arecor Therapeutics secures licensing deal for AT351, pioneering ready-to-dilute critical care therapy

Arecor Therapeutics plc, a globally focused biopharmaceutical company, has entered into an exclusive licensing agreement for AT351, a breakthrough ready-to-dilute (RTD) liquid formulation for critical ... Read More